Are you over 18 and want to see adult content?
More Annotations
A complete backup of https://muntfish.com
Are you over 18 and want to see adult content?
A complete backup of https://impacttest.com
Are you over 18 and want to see adult content?
A complete backup of https://fastestknowntime.com
Are you over 18 and want to see adult content?
A complete backup of https://tanstack.com
Are you over 18 and want to see adult content?
A complete backup of https://workersonboard.com
Are you over 18 and want to see adult content?
A complete backup of https://anztheme.com
Are you over 18 and want to see adult content?
A complete backup of https://mypress.mx
Are you over 18 and want to see adult content?
A complete backup of https://chimprewriter.com
Are you over 18 and want to see adult content?
A complete backup of https://caverion.com
Are you over 18 and want to see adult content?
A complete backup of https://isoacoustics.com
Are you over 18 and want to see adult content?
A complete backup of https://traveldailynews.gr
Are you over 18 and want to see adult content?
A complete backup of https://philadelphiaeagleslockerroom.com
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of www.bbc.com/turkce/haberler-dunya-51638721
Are you over 18 and want to see adult content?
A complete backup of www.bbc.co.uk/sport/football/51623058
Are you over 18 and want to see adult content?
A complete backup of www.bbc.co.uk/news/stories-51633897
Are you over 18 and want to see adult content?
A complete backup of www.nieuwsblad.be/cnt/dmf20200226_04865769
Are you over 18 and want to see adult content?
A complete backup of news.now.com/home/life/player?newsId=382262
Are you over 18 and want to see adult content?
A complete backup of www.cbssports.com/nba/news/lakers-vs-pelicans-odds-line-spread-2020-nba-picks-feb-25-predictions-from-simul
Are you over 18 and want to see adult content?
Text
sourced from PPI.
PPRI PHARMA BRIEF: AUSTRIA 2019 PPRI Pharma Brief: Austria 2019 Pharmaceutical Pricing and Reimbursement Information (PPRI) Pharma Briefs Series Commissioned by the Austrian Federal MinistrySABINE VOGLER
Head of the Pharmacoeconomics Department. Head of WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies. sabine.vogler@goeg.at. + 43 1 515 61 147. Mag. Dr. Sabine Vogler, Director of the WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, is head of the Pharmacoeconomics Department. She is aABOUT | WHOCC PPRI
This section provides general information about the aims, team and background of the WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies. Vision and Mission About us Team NewsContact
THE PHARMACEUTICAL SYSTEM OF THE NETHERLANDS The pharmaceutical system of the Netherlands A comparative analysis between the Dutch out-patient pharmaceutical system, in particular the pricing and reimbursement characteristics, and those of the otherEuropean Union
TENDERING OF PHARMACEUTICALS IN EU MEMBER STATES AND EEA 7 2 Results 2.1 Tendering Systems in the EU Member States and EEA countries Public tendering of pharmaceuticals is widely used around Europe. In 18 out of the 19 coun- A COST/BENEFIT ANALYSIS OF SELF- CARE SYSTEMS IN THE A cost/benefit analysis of self-care systems in the European Union April, 2015 5 Abstract Due to the recent economic environment and the accompanying financial pressure on DISCOUNTS AND REBATES GRANTED TO PUBLIC PAYERS FOR Introduction Research Article Citation: Vogler S, Zimmermann N, Habl C, Piessnegger J, Bucsics A. Discounts and rebates granted to public payers for medicines in European countries. Southern Med Review (2012) 5;1:38-46 Governments’ medicines policies aim to provide to their EUROPEAN PUBLIC HEALTH WEEK Lunchtime seminar on the topic: Policies to support vulnerable groups during the pandemic. We are honoured that the event may count on the participation of an honourable member of the cabinet of the Portuguese government, currently hosting the EU presidency with the motto “Time to deliver: a fair, green and digital recovery”. PPRI PHARMA BRIEF: FRANCE 2020 PPRI Pharma Brief: France 2020 Pharmaceutical Pricing and Reimbursement Information (PPRI) Pharma Briefs Series Commissioned by the Austrian Federal Ministry PHARMA PRICE INFORMATION (PPI) The Pharmacoeconomics Department operates the Pharma Price Information System (PPI), which provides up-to-date and independent price data for medicines in 30 European countries. Any party interested can request price information from the PPI service for a charge which covers the experts' working time. See FAQs of how to access price informationsourced from PPI.
PPRI PHARMA BRIEF: AUSTRIA 2019 PPRI Pharma Brief: Austria 2019 Pharmaceutical Pricing and Reimbursement Information (PPRI) Pharma Briefs Series Commissioned by the Austrian Federal MinistrySABINE VOGLER
Head of the Pharmacoeconomics Department. Head of WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies. sabine.vogler@goeg.at. + 43 1 515 61 147. Mag. Dr. Sabine Vogler, Director of the WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, is head of the Pharmacoeconomics Department. She is aABOUT | WHOCC PPRI
This section provides general information about the aims, team and background of the WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies. Vision and Mission About us Team NewsContact
THE PHARMACEUTICAL SYSTEM OF THE NETHERLANDS The pharmaceutical system of the Netherlands A comparative analysis between the Dutch out-patient pharmaceutical system, in particular the pricing and reimbursement characteristics, and those of the otherEuropean Union
TENDERING OF PHARMACEUTICALS IN EU MEMBER STATES AND EEA 7 2 Results 2.1 Tendering Systems in the EU Member States and EEA countries Public tendering of pharmaceuticals is widely used around Europe. In 18 out of the 19 coun- A COST/BENEFIT ANALYSIS OF SELF- CARE SYSTEMS IN THE A cost/benefit analysis of self-care systems in the European Union April, 2015 5 Abstract Due to the recent economic environment and the accompanying financial pressure on DISCOUNTS AND REBATES GRANTED TO PUBLIC PAYERS FOR Introduction Research Article Citation: Vogler S, Zimmermann N, Habl C, Piessnegger J, Bucsics A. Discounts and rebates granted to public payers for medicines in European countries. Southern Med Review (2012) 5;1:38-46 Governments’ medicines policies aim to provide to their ENGLISH | DATENPLATTFORM COVID Information. In order to carry out research into SARS-CoV-2 and COVID-19, academic and scientific institutions can be given permission to use data from the Austrian epidemiological reporting system (Österreichisches Epidemiologisches Meldesystem, EMS), which is why the Federal Ministry of Social Affairs, Health, Care and Consumer Protection (Bundesministerium für Soziales, Gesundheit, Pflege PHARMA PRICE INFORMATION The Pharma Price Information (PPI) service of GÖG provides, upon request, quick, reliable and independent information on pharmaceutical prices in all member states of the European Union (EU), Norway, Switzerland and the UK. Within Europe, medicine prices vary considerably. Despite a common currency – the euro – a comparison of prices remains difficult and requires considerable resources 2020 STANDARDS FOR HEALTH PROMOTINGHOSPITALS AND HEALTH OptiMedisAG 32 Standard 1: Demonstrating organizational commitment for HPH. Objective: The organization is committed to orient their governance models, policies,TEAM | WHOCC PPRI
Staff of the Pharmacoeconomics Department of GÖG and experts of other GÖG departments and structures who collaborate with the Department on pharmaceutical policy topics have long-term experience in pharmaceutical pricing and reimbursement analysis in European countries and beyond and in-depth knowledge of medicines prices and methodology development. ONLINE SUMMER SCHOOL PHARMACEUTICAL PRICING AND 5-9 July 2021. The WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies is pleased to announce the first Online Summer School on Pharmaceutical Pricing and Reimbursement Policies. Addressing a global audience of policy-makers and technical experts in public authorities who work on pricing and reimbursement of medicinesWELCOME TO JASMIN
Search Repository Search the repository using a full range of fields. Use the search field at the top of the page for a quick search. GLOSSARY OF PHARMACEUTICAL TERMS Owner and Edito r: Gesundheit Österreich GmbH, Stubenring 6, A-1010 Vienna, Phone +43 1 515 61, Fax 513 84 72, Homepage: www.goeg.at BRAZIL PHARMACEUTICAL PRICING AND REIMBURSEMENT POLICIES Adriana M. Ivama Brummell1; Misani A. Kanamota Ronchini1; Daniella Pingret Kipman1; Fernando de Moraes Rego1; J. Ricardo Santana1; 1Medicines’ Market Regulation hamber Executive Secretariat (SMED)/razilian Health Regulatory Agency (Anvisa), rasília, ra zil; e-mail: Adriana.ivama@anvisa.gov.br Brazil Pharmaceutical pricing and reimbursement policies EX-FACTORY PRICE (MANUFACTURER PRICE, EX-MANUFACTURER The manufacturer’s posted price of a pharmaceutical or other products. In German: Fabriksabgabepreis / Herstellerpreis Preis, zu dem ein pharmazeutisches Unternehmen Arzneimittel und andere Produkte anbietet und abgibt.HOME | WHOCC PPRI
Home | WHOCC PPRI
ABOUT US | GESUNDHEIT ÖSTERREICH GMBHSEE MORE ON GOEG.AT EUROPEAN PUBLIC HEALTH WEEK Lunchtime seminar on the topic: Policies to support vulnerable groups during the pandemic. We are honoured that the event may count on the participation of an honourable member of the cabinet of the Portuguese government, currently hosting the EU presidency with the motto “Time to deliver: a fair, green and digital recovery”. PPRI PHARMA BRIEF: AUSTRIA 2019 PPRI Pharma Brief: Austria 2019 Pharmaceutical Pricing and Reimbursement Information (PPRI) Pharma Briefs Series Commissioned by the Austrian Federal Ministry PPRI PHARMA BRIEF: FRANCE 2020 PPRI Pharma Brief: France 2020 Pharmaceutical Pricing and Reimbursement Information (PPRI) Pharma Briefs Series Commissioned by the Austrian Federal Ministry PHARMA PRICE INFORMATION (PPI) The Pharmacoeconomics Department operates the Pharma Price Information System (PPI), which provides up-to-date and independent price data for medicines in 30 European countries. Any party interested can request price information from the PPI service for a charge which covers the experts' working time. See FAQs of how to access price informationsourced from PPI.
SABINE VOGLER
Head of the Pharmacoeconomics Department. Head of WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies. sabine.vogler@goeg.at. + 43 1 515 61 147. Mag. Dr. Sabine Vogler, Director of the WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, is head of the Pharmacoeconomics Department. She is a THE AUSTRIAN HEALTH CARE SYSTEM Preface 1 Preface Good health is an invaluable asset. Illness and impairment due to disease may. reduce people’s quality of life to a con-siderable extent – especially if they have SHORT PPRI PHARMA PROFILE Short PPRI Pharma Profile 2017 Turkey 2 The PPRI Pharma Profile 2017 is designed to comprise up-to-date information as of 2017 (or latest available year) about pharmaceutical pricing and reimbursement in boththe out-patient
TENDERING OF PHARMACEUTICALS IN EU MEMBER STATES AND EEA 7 2 Results 2.1 Tendering Systems in the EU Member States and EEA countries Public tendering of pharmaceuticals is widely used around Europe. In 18 out of the 19 coun- EUROPEAN OBSERVATORY ON HEALTH SYSTEMS AND POLICIES NEW European Observatory on Health Systems and Policies NEW HIT Published by the European Observatory on Health Systems and Policies www.healthobservatory.eu/ ABOUT US | GESUNDHEIT ÖSTERREICH GMBHSEE MORE ON GOEG.AT EUROPEAN PUBLIC HEALTH WEEK Lunchtime seminar on the topic: Policies to support vulnerable groups during the pandemic. We are honoured that the event may count on the participation of an honourable member of the cabinet of the Portuguese government, currently hosting the EU presidency with the motto “Time to deliver: a fair, green and digital recovery”. PPRI PHARMA BRIEF: AUSTRIA 2019 PPRI Pharma Brief: Austria 2019 Pharmaceutical Pricing and Reimbursement Information (PPRI) Pharma Briefs Series Commissioned by the Austrian Federal Ministry PPRI PHARMA BRIEF: FRANCE 2020 PPRI Pharma Brief: France 2020 Pharmaceutical Pricing and Reimbursement Information (PPRI) Pharma Briefs Series Commissioned by the Austrian Federal Ministry PHARMA PRICE INFORMATION (PPI) The Pharmacoeconomics Department operates the Pharma Price Information System (PPI), which provides up-to-date and independent price data for medicines in 30 European countries. Any party interested can request price information from the PPI service for a charge which covers the experts' working time. See FAQs of how to access price informationsourced from PPI.
SABINE VOGLER
Head of the Pharmacoeconomics Department. Head of WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies. sabine.vogler@goeg.at. + 43 1 515 61 147. Mag. Dr. Sabine Vogler, Director of the WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, is head of the Pharmacoeconomics Department. She is a THE AUSTRIAN HEALTH CARE SYSTEM Preface 1 Preface Good health is an invaluable asset. Illness and impairment due to disease may. reduce people’s quality of life to a con-siderable extent – especially if they have SHORT PPRI PHARMA PROFILE Short PPRI Pharma Profile 2017 Turkey 2 The PPRI Pharma Profile 2017 is designed to comprise up-to-date information as of 2017 (or latest available year) about pharmaceutical pricing and reimbursement in boththe out-patient
TENDERING OF PHARMACEUTICALS IN EU MEMBER STATES AND EEA 7 2 Results 2.1 Tendering Systems in the EU Member States and EEA countries Public tendering of pharmaceuticals is widely used around Europe. In 18 out of the 19 coun- EUROPEAN OBSERVATORY ON HEALTH SYSTEMS AND POLICIES NEW European Observatory on Health Systems and Policies NEW HIT Published by the European Observatory on Health Systems and Policies www.healthobservatory.eu/ INTERNATIONAL ACTIVITIES International Activities. Our mission is to maintain and improve quality, efficacy, and efficiency in the public health system. We offer a wide range of expertise from health care planning, economics, pharmaceuticals, health literacy, health promotion, and health ENGLISH | DATENPLATTFORM COVID Information. In order to carry out research into SARS-CoV-2 and COVID-19, academic and scientific institutions can be given permission to use data from the Austrian epidemiological reporting system (Österreichisches Epidemiologisches Meldesystem, EMS), which is why the Federal Ministry of Social Affairs, Health, Care and Consumer Protection (Bundesministerium für Soziales, Gesundheit, Pflege PHARMA PRICE INFORMATION The Pharma Price Information (PPI) service of GÖG provides, upon request, quick, reliable and independent information on pharmaceutical prices in all member states of the European Union (EU), Norway, Switzerland and the UK. Within Europe, medicine prices vary considerably. Despite a common currency – the euro – a comparison of prices remains difficult and requires considerable resources FINANCIAL BURDEN OF HOUSEHOLD ARISING FROM MEDICINES Medicines can pose a financial burden for patients and their caregivers.In this interview led by Nina Zimmermann, Sabine Vogler, head of Pharmacoeconomics at the Austrian National Public Health Institute talks about co-payments for medicines in European countries and protective measures to ensure that no one is left behind.. Interview: Financial burden of household arising from medicinesAGREEMENT - GOEG.AT
Gesundheit Österreich Beratungs GmbH Stubenring 6 1010 Vienna T: +43 1 406 68 98 -418/-420 T Hours: Mo-We 9:30 am -12:30 pm SDS-Agreement@goeg.at ABOUT US | WHOCC PPRI Our research, policy-advice and capacity-building activities center around the topics of price information, pricing policies and reimbursement of medicines: experts of the GÖG Pharmacoeconomics Department, a WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, have been working for more than two decades on pharmaceutical pricing and reimbursement in Austria, EuropeTEAM | WHOCC PPRI
Staff of the Pharmacoeconomics Department of GÖG and experts of other GÖG departments and structures who collaborate with the Department on pharmaceutical policy topics have long-term experience in pharmaceutical pricing and reimbursement analysis in European countries and beyond and in-depth knowledge of medicines prices and methodology development. REIMBURSEMENT RESTRICTION MODERATELY DECREASES Recent policies to reduce drug costs and the budget deficit in Croatia: impact and example to others. L. V. ončina. and . T. Strizrep (Croatian Institute for Health Insurance, Zagreb, Croatia), B. Godman (KI, Sweden), V. Vlahović-Palčevski(Rijeka UniversityHospital, Croatia)
PHIS PHARMA PROFILE TEMPLATE PHIS Pharma Profile 2010 United Kingdom VIII 2010) - is payable in respect of each item supplied. There is a system of exemptions under which items are supplied free ofFINLAND PPRI 2007
Pharmaceutical Pricing and Reimbursement Information FINLAND Pharma Profile Final version, June 2007 PPRI Participant(s) Institution1: Sirpa Peura, Association of Finnish Pharmacies (AFP) ABOUT US | GESUNDHEIT ÖSTERREICH GMBHSEE MORE ON GOEG.AT EUROPEAN PUBLIC HEALTH WEEK Lunchtime seminar on the topic: Policies to support vulnerable groups during the pandemic. We are honoured that the event may count on the participation of an honourable member of the cabinet of the Portuguese government, currently hosting the EU presidency with the motto “Time to deliver: a fair, green and digital recovery”. PPRI PHARMA BRIEF: AUSTRIA 2019 PPRI Pharma Brief: Austria 2019 Pharmaceutical Pricing and Reimbursement Information (PPRI) Pharma Briefs Series Commissioned by the Austrian Federal Ministry PPRI PHARMA BRIEF: FRANCE 2020 PPRI Pharma Brief: France 2020 Pharmaceutical Pricing and Reimbursement Information (PPRI) Pharma Briefs Series Commissioned by the Austrian Federal Ministry PHARMA PRICE INFORMATION (PPI) The Pharmacoeconomics Department operates the Pharma Price Information System (PPI), which provides up-to-date and independent price data for medicines in 30 European countries. Any party interested can request price information from the PPI service for a charge which covers the experts' working time. See FAQs of how to access price informationsourced from PPI.
SABINE VOGLER
Head of the Pharmacoeconomics Department. Head of WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies. sabine.vogler@goeg.at. + 43 1 515 61 147. Mag. Dr. Sabine Vogler, Director of the WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, is head of the Pharmacoeconomics Department. She is a THE AUSTRIAN HEALTH CARE SYSTEM Preface 1 Preface Good health is an invaluable asset. Illness and impairment due to disease may. reduce people’s quality of life to a con-siderable extent – especially if they have SHORT PPRI PHARMA PROFILE Short PPRI Pharma Profile 2017 Turkey 2 The PPRI Pharma Profile 2017 is designed to comprise up-to-date information as of 2017 (or latest available year) about pharmaceutical pricing and reimbursement in boththe out-patient
TENDERING OF PHARMACEUTICALS IN EU MEMBER STATES AND EEA 7 2 Results 2.1 Tendering Systems in the EU Member States and EEA countries Public tendering of pharmaceuticals is widely used around Europe. In 18 out of the 19 coun-PPRI PHARMA PROFILE
IV The PPRI Pharma Profile 2018 is designed to comprise up-to-date information as of 2018 (or latest available year) about pharmaceutical pricing and reimbursement in both the out-patient ABOUT US | GESUNDHEIT ÖSTERREICH GMBHSEE MORE ON GOEG.AT EUROPEAN PUBLIC HEALTH WEEK Lunchtime seminar on the topic: Policies to support vulnerable groups during the pandemic. We are honoured that the event may count on the participation of an honourable member of the cabinet of the Portuguese government, currently hosting the EU presidency with the motto “Time to deliver: a fair, green and digital recovery”. PPRI PHARMA BRIEF: AUSTRIA 2019 PPRI Pharma Brief: Austria 2019 Pharmaceutical Pricing and Reimbursement Information (PPRI) Pharma Briefs Series Commissioned by the Austrian Federal Ministry PPRI PHARMA BRIEF: FRANCE 2020 PPRI Pharma Brief: France 2020 Pharmaceutical Pricing and Reimbursement Information (PPRI) Pharma Briefs Series Commissioned by the Austrian Federal Ministry PHARMA PRICE INFORMATION (PPI) The Pharmacoeconomics Department operates the Pharma Price Information System (PPI), which provides up-to-date and independent price data for medicines in 30 European countries. Any party interested can request price information from the PPI service for a charge which covers the experts' working time. See FAQs of how to access price informationsourced from PPI.
SABINE VOGLER
Head of the Pharmacoeconomics Department. Head of WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies. sabine.vogler@goeg.at. + 43 1 515 61 147. Mag. Dr. Sabine Vogler, Director of the WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, is head of the Pharmacoeconomics Department. She is a THE AUSTRIAN HEALTH CARE SYSTEM Preface 1 Preface Good health is an invaluable asset. Illness and impairment due to disease may. reduce people’s quality of life to a con-siderable extent – especially if they have SHORT PPRI PHARMA PROFILE Short PPRI Pharma Profile 2017 Turkey 2 The PPRI Pharma Profile 2017 is designed to comprise up-to-date information as of 2017 (or latest available year) about pharmaceutical pricing and reimbursement in boththe out-patient
TENDERING OF PHARMACEUTICALS IN EU MEMBER STATES AND EEA 7 2 Results 2.1 Tendering Systems in the EU Member States and EEA countries Public tendering of pharmaceuticals is widely used around Europe. In 18 out of the 19 coun-PPRI PHARMA PROFILE
IV The PPRI Pharma Profile 2018 is designed to comprise up-to-date information as of 2018 (or latest available year) about pharmaceutical pricing and reimbursement in both the out-patient INTERNATIONAL ACTIVITIES International Activities. Our mission is to maintain and improve quality, efficacy, and efficiency in the public health system. We offer a wide range of expertise from health care planning, economics, pharmaceuticals, health literacy, health promotion, and health ENGLISH | DATENPLATTFORM COVID Information. In order to carry out research into SARS-CoV-2 and COVID-19, academic and scientific institutions can be given permission to use data from the Austrian epidemiological reporting system (Österreichisches Epidemiologisches Meldesystem, EMS), which is why the Federal Ministry of Social Affairs, Health, Care and Consumer Protection (Bundesministerium für Soziales, Gesundheit, Pflege PHARMA PRICE INFORMATION The Pharma Price Information (PPI) service of GÖG provides, upon request, quick, reliable and independent information on pharmaceutical prices in all member states of the European Union (EU), Norway, Switzerland and the UK. Within Europe, medicine prices vary considerably. Despite a common currency – the euro – a comparison of prices remains difficult and requires considerable resources FINANCIAL BURDEN OF HOUSEHOLD ARISING FROM MEDICINES Medicines can pose a financial burden for patients and their caregivers.In this interview led by Nina Zimmermann, Sabine Vogler, head of Pharmacoeconomics at the Austrian National Public Health Institute talks about co-payments for medicines in European countries and protective measures to ensure that no one is left behind.. Interview: Financial burden of household arising from medicinesAGREEMENT - GOEG.AT
Gesundheit Österreich Beratungs GmbH Stubenring 6 1010 Vienna T: +43 1 406 68 98 -418/-420 T Hours: Mo-We 9:30 am -12:30 pm SDS-Agreement@goeg.at ABOUT US | WHOCC PPRI About us. Our research, policy-advice and capacity-building activities center around the topics of price information, pricing policies and reimbursement of medicines: experts of the GÖG Pharmacoeconomics Department, a WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, have been working for more than two decades onTEAM | WHOCC PPRI
Staff of the Pharmacoeconomics Department of GÖG and experts of other GÖG departments and structures who collaborate with the Department on pharmaceutical policy topics have long-term experience in pharmaceutical pricing and reimbursement analysis in European countries and beyond and in-depth knowledge of medicines prices and methodology development. GLOSSARY | WHOCC PPRI Die Gesundheit Österreich GmbH (GÖG) ist das nationale Forschungs- und Planungsinstitut für das Gesundheitswesen und die Kompetenz- und Förderstelle für Gesundheitsförderung in Österreich. REIMBURSEMENT RESTRICTION MODERATELY DECREASES Recent policies to reduce drug costs and the budget deficit in Croatia: impact and example to others. L. V. ončina. and . T. Strizrep (Croatian Institute for Health Insurance, Zagreb, Croatia), B. Godman (KI, Sweden), V. Vlahović-Palčevski(Rijeka UniversityHospital, Croatia)
PHIS PHARMA PROFILE TEMPLATE PHIS Pharma Profile 2010 United Kingdom VIII 2010) - is payable in respect of each item supplied. There is a system of exemptions under which items are supplied free of EUROPEAN PUBLIC HEALTH WEEK Lunchtime seminar on the topic: Policies to support vulnerable groups during the pandemic. We are honoured that the event may count on the participation of an honourable member of the cabinet of the Portuguese government, currently hosting the EU presidency with the motto “Time to deliver: a fair, green and digital recovery”. PHARMA PRICE INFORMATION (PPI) The Pharmacoeconomics Department operates the Pharma Price Information System (PPI), which provides up-to-date and independent price data for medicines in 30 European countries. Any party interested can request price information from the PPI service for a charge which covers the experts' working time. See FAQs of how to access price informationsourced from PPI.
PPRI PHARMA BRIEF: AUSTRIA 2019 PPRI Pharma Brief: Austria 2019 Pharmaceutical Pricing and Reimbursement Information (PPRI) Pharma Briefs Series Commissioned by the Austrian Federal MinistrySABINE VOGLER
Head of the Pharmacoeconomics Department. Head of WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies. sabine.vogler@goeg.at. + 43 1 515 61 147. Mag. Dr. Sabine Vogler, Director of the WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, is head of the Pharmacoeconomics Department. She is a EURIPID GUIDANCE DOCUMENT ON EXTERNAL REFERENCE PRICING Background and Research Question: The comparison of the prices of pharmaceuticals is an important element of a popular policy tool in Europe, known as ‘External Reference Pricing’ (ERP). Albeit being a commonly used policy instrument, ERP is often challenged by stakeholders by claiming potential negative effects on patients’ access or that it is hampering uptake of products in a market. GLOSSARY OF PHARMACEUTICAL TERMS Owner and Edito r: Gesundheit Österreich GmbH, Stubenring 6, A-1010 Vienna, Phone +43 1 515 61, Fax 513 84 72, Homepage: www.goeg.at TENDERING OF PHARMACEUTICALS IN EU MEMBER STATES AND EEA 7 2 Results 2.1 Tendering Systems in the EU Member States and EEA countries Public tendering of pharmaceuticals is widely used around Europe. In 18 out of the 19 coun- EUROPEAN PUBLIC HEALTH WEEK Lunchtime seminar on the topic: Policies to support vulnerable groups during the pandemic. We are honoured that the event may count on the participation of an honourable member of the cabinet of the Portuguese government, currently hosting the EU presidency with the motto “Time to deliver: a fair, green and digital recovery”. PHARMA PRICE INFORMATION (PPI) The Pharmacoeconomics Department operates the Pharma Price Information System (PPI), which provides up-to-date and independent price data for medicines in 30 European countries. Any party interested can request price information from the PPI service for a charge which covers the experts' working time. See FAQs of how to access price informationsourced from PPI.
PPRI PHARMA BRIEF: AUSTRIA 2019 PPRI Pharma Brief: Austria 2019 Pharmaceutical Pricing and Reimbursement Information (PPRI) Pharma Briefs Series Commissioned by the Austrian Federal MinistrySABINE VOGLER
Head of the Pharmacoeconomics Department. Head of WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies. sabine.vogler@goeg.at. + 43 1 515 61 147. Mag. Dr. Sabine Vogler, Director of the WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, is head of the Pharmacoeconomics Department. She is a EURIPID GUIDANCE DOCUMENT ON EXTERNAL REFERENCE PRICING Background and Research Question: The comparison of the prices of pharmaceuticals is an important element of a popular policy tool in Europe, known as ‘External Reference Pricing’ (ERP). Albeit being a commonly used policy instrument, ERP is often challenged by stakeholders by claiming potential negative effects on patients’ access or that it is hampering uptake of products in a market. GLOSSARY OF PHARMACEUTICAL TERMS Owner and Edito r: Gesundheit Österreich GmbH, Stubenring 6, A-1010 Vienna, Phone +43 1 515 61, Fax 513 84 72, Homepage: www.goeg.at TENDERING OF PHARMACEUTICALS IN EU MEMBER STATES AND EEA 7 2 Results 2.1 Tendering Systems in the EU Member States and EEA countries Public tendering of pharmaceuticals is widely used around Europe. In 18 out of the 19 coun- DISCOUNTS AND REBATES GRANTED TO PUBLIC PAYERS FOR Introduction Research Article Citation: Vogler S, Zimmermann N, Habl C, Piessnegger J, Bucsics A. Discounts and rebates granted to public payers for medicines in European countries. Southern Med Review (2012) 5;1:38-46 Governments’ medicines policies aim to provide to their A COST/BENEFIT ANALYSIS OF SELF- CARE SYSTEMS IN THE A cost/benefit analysis of self-care systems in the European Union April, 2015 5 Abstract Due to the recent economic environment and the accompanying financial pressure on TENDERING FOR OFF‐PATENT OUTPATIENT MEDICINES: LESSONS JPHS 2017, : – ª 2017 Royal Pharmaceutical Society Received November 30, 2016 Accepted April 11, 2017 DOI 10.1111/jphs.12180 ISSN 1759-8885 Correspondence: Sabine Vogler,TEAM | WHOCC PPRI
Staff of the Pharmacoeconomics Department of GÖG and experts of other GÖG departments and structures who collaborate with the Department on pharmaceutical policy topics have long-term experience in pharmaceutical pricing and reimbursement analysis in European countries and beyond and in-depth knowledge of medicines prices and methodology development. GLOSSARY | WHOCC PPRI Die Gesundheit Österreich GmbH (GÖG) ist das nationale Forschungs- und Planungsinstitut für das Gesundheitswesen und die Kompetenz- und Förderstelle für Gesundheitsförderung in Österreich. ONLINE SUMMER SCHOOL PHARMACEUTICAL PRICING AND 5-9 July 2021. The WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies is pleased to announce the first Online Summer School on Pharmaceutical Pricing and Reimbursement Policies. Addressing a global audience of policy-makers and technical experts in public authorities who work on pricing and reimbursement of medicines RESEARCH, TECHNICAL SUPPORT AND TRAININGS Research, technical support and trainings. Because of their access to medicine prices and their expertise in the existing pharmaceutical systems, experts of the Pharmacoeconomics Department have been conducting research on medicine prices (international medicine price comparisons, impact of discounts and rebates, the relevance ofwholesale and
PPI | WHOCC PPRI
The ‘Pharma Price Information’ (PPI) service offers, at request and against a charge to cover the experts’ working time, reliable price data of medicines and molecules defined by MANAGED ENTRY AGREEMENT (MEA) Managed entry agreement (MEA) An arrangement between a manufacturer and payer/provider that enables access to (coverage/reimbursement of) a health technology subject to specified conditions. These arrangements can use a variety of mechanisms and are usually classified into financial-based and performance-based MEA. EX-FACTORY PRICE (MANUFACTURER PRICE, EX The manufacturer’s posted price of a pharmaceutical or other products. In German: Fabriksabgabepreis / Herstellerpreis Preis, zu dem ein pharmazeutisches Unternehmen Arzneimittel und andere Produkte anbietet und abgibt. REIMBURSEMENT RESTRICTION MODERATELY DECREASES Recent policies to reduce drug costs and the budget deficit in Croatia: impact and example to others. L. V. ončina. and . T. Strizrep (Croatian Institute for Health Insurance, Zagreb, Croatia), B. Godman (KI, Sweden), V. Vlahović-Palčevski(Rijeka UniversityHospital, Croatia)
PHIS PHARMA PROFILE TEMPLATE PHIS Pharma Profile 2010 United Kingdom VIII 2010) - is payable in respect of each item supplied. There is a system of exemptions under which items are supplied free of EUROPEAN OBSERVATORY ON HEALTH SYSTEMS AND POLICIES NEW European Observatory on Health Systems and Policies NEW HIT Published by the European Observatory on Health Systems and Policies www.healthobservatory.eu/ EUROPEAN PUBLIC HEALTH WEEK Lunchtime seminar on the topic: Policies to support vulnerable groups during the pandemic. We are honoured that the event may count on the participation of an honourable member of the cabinet of the Portuguese government, currently hosting the EU presidency with the motto “Time to deliver: a fair, green and digital recovery”. PHARMA PRICE INFORMATION (PPI) The Pharmacoeconomics Department operates the Pharma Price Information System (PPI), which provides up-to-date and independent price data for medicines in 30 European countries. Any party interested can request price information from the PPI service for a charge which covers the experts' working time. See FAQs of how to access price informationsourced from PPI.
SABINE VOGLER
Head of the Pharmacoeconomics Department. Head of WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies. sabine.vogler@goeg.at. + 43 1 515 61 147. Mag. Dr. Sabine Vogler, Director of the WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, is head of the Pharmacoeconomics Department. She is aTEAM | WHOCC PPRI
Staff of the Pharmacoeconomics Department of GÖG and experts of other GÖG departments and structures who collaborate with the Department on pharmaceutical policy topics have long-term experience in pharmaceutical pricing and reimbursement analysis in European countries and beyond and in-depth knowledge of medicines prices and methodology development.PPRI PHARMA PROFILE
IV The PPRI Pharma Profile 2018 is designed to comprise up-to-date information as of 2018 (or latest available year) about pharmaceutical pricing and reimbursement in both the out-patient EURIPID GUIDANCE DOCUMENT ON EXTERNAL REFERENCE PRICING Background and Research Question: The comparison of the prices of pharmaceuticals is an important element of a popular policy tool in Europe, known as ‘External Reference Pricing’ (ERP). Albeit being a commonly used policy instrument, ERP is often challenged by stakeholders by claiming potential negative effects on patients’ access or that it is hampering uptake of products in a market. TENDERING OF PHARMACEUTICALS IN EU MEMBER STATES AND EEA 7 2 Results 2.1 Tendering Systems in the EU Member States and EEA countries Public tendering of pharmaceuticals is widely used around Europe. In 18 out of the 19 coun- A COST/BENEFIT ANALYSIS OF SELF- CARE SYSTEMS IN THE A cost/benefit analysis of self-care systems in the European Union April, 2015 5 Abstract Due to the recent economic environment and the accompanying financial pressure on DISCOUNTS AND REBATES GRANTED TO PUBLIC PAYERS FOR Introduction Research Article Citation: Vogler S, Zimmermann N, Habl C, Piessnegger J, Bucsics A. Discounts and rebates granted to public payers for medicines in European countries. Southern Med Review (2012) 5;1:38-46 Governments’ medicines policies aim to provide to theirFINLAND PPRI 2007
Pharmaceutical Pricing and Reimbursement Information FINLAND Pharma Profile Final version, June 2007 PPRI Participant(s) Institution1: Sirpa Peura, Association of Finnish Pharmacies (AFP) EUROPEAN PUBLIC HEALTH WEEK Lunchtime seminar on the topic: Policies to support vulnerable groups during the pandemic. We are honoured that the event may count on the participation of an honourable member of the cabinet of the Portuguese government, currently hosting the EU presidency with the motto “Time to deliver: a fair, green and digital recovery”. PHARMA PRICE INFORMATION (PPI) The Pharmacoeconomics Department operates the Pharma Price Information System (PPI), which provides up-to-date and independent price data for medicines in 30 European countries. Any party interested can request price information from the PPI service for a charge which covers the experts' working time. See FAQs of how to access price informationsourced from PPI.
SABINE VOGLER
Head of the Pharmacoeconomics Department. Head of WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies. sabine.vogler@goeg.at. + 43 1 515 61 147. Mag. Dr. Sabine Vogler, Director of the WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, is head of the Pharmacoeconomics Department. She is aTEAM | WHOCC PPRI
Staff of the Pharmacoeconomics Department of GÖG and experts of other GÖG departments and structures who collaborate with the Department on pharmaceutical policy topics have long-term experience in pharmaceutical pricing and reimbursement analysis in European countries and beyond and in-depth knowledge of medicines prices and methodology development.PPRI PHARMA PROFILE
IV The PPRI Pharma Profile 2018 is designed to comprise up-to-date information as of 2018 (or latest available year) about pharmaceutical pricing and reimbursement in both the out-patient EURIPID GUIDANCE DOCUMENT ON EXTERNAL REFERENCE PRICING Background and Research Question: The comparison of the prices of pharmaceuticals is an important element of a popular policy tool in Europe, known as ‘External Reference Pricing’ (ERP). Albeit being a commonly used policy instrument, ERP is often challenged by stakeholders by claiming potential negative effects on patients’ access or that it is hampering uptake of products in a market. TENDERING OF PHARMACEUTICALS IN EU MEMBER STATES AND EEA 7 2 Results 2.1 Tendering Systems in the EU Member States and EEA countries Public tendering of pharmaceuticals is widely used around Europe. In 18 out of the 19 coun- A COST/BENEFIT ANALYSIS OF SELF- CARE SYSTEMS IN THE A cost/benefit analysis of self-care systems in the European Union April, 2015 5 Abstract Due to the recent economic environment and the accompanying financial pressure on DISCOUNTS AND REBATES GRANTED TO PUBLIC PAYERS FOR Introduction Research Article Citation: Vogler S, Zimmermann N, Habl C, Piessnegger J, Bucsics A. Discounts and rebates granted to public payers for medicines in European countries. Southern Med Review (2012) 5;1:38-46 Governments’ medicines policies aim to provide to theirFINLAND PPRI 2007
Pharmaceutical Pricing and Reimbursement Information FINLAND Pharma Profile Final version, June 2007 PPRI Participant(s) Institution1: Sirpa Peura, Association of Finnish Pharmacies (AFP) ABOUT US | GESUNDHEIT ÖSTERREICH GMBH The Austrian National Public Health Institute (Gesundheit Österreich GmbH, GÖG) is the institution responsible for researching and planning public healthcare in Austria, and also acts as the national competence and funding centre for the promotion of health. Set up by federal law on 1 August 2006, GÖG has the federal government as its sole shareholder, represented by the Ministry of Health. PHARMA PRICE INFORMATION The Pharma Price Information (PPI) service of GÖG provides, upon request, quick, reliable and independent information on pharmaceutical prices in all member states of the European Union (EU), Norway, Switzerland and the UK. Within Europe, medicine prices vary considerably. Despite a common currency – the euro – a comparison of prices remains difficult and requires considerable resources CALL FOR ABSTRACTS: 28TH INTERNATIONAL CONFERENCE ONTRANSLATE THISPAGE
Call for Abstracts: 28th International Conference on Health Promoting Hospitals and Health Services (HPH) ABOUT US | WHOCC PPRI Our research, policy-advice and capacity-building activities center around the topics of price information, pricing policies and reimbursement of medicines: experts of the GÖG Pharmacoeconomics Department, a WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, have been working for more than two decades on pharmaceutical pricing and reimbursement in Austria, Europe RESEARCH | WHOCC PPRI Gesundheit Österreich GmbH / Austrian National Public Health Institute Pharmacoeconomics Department Stubenring 6 1010 Vienna, Austria whocc@goeg.at RESEARCH, TECHNICAL SUPPORT AND TRAININGS Because of their access to medicine prices and their expertise in the existing pharmaceutical systems, experts of the Pharmacoeconomics Department have been conducting research on medicine prices (international medicine price comparisons, impact of discounts and rebates, the relevance of wholesale and pharmacy remuneration as part of medicine prices) and have been providing technical support ONLINE SUMMER SCHOOL PHARMACEUTICAL PRICING AND 5-9 July 2021. The WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies is pleased to announce the first Online Summer School on Pharmaceutical Pricing and Reimbursement Policies. Addressing a global audience of policy-makers and technical experts in public authorities who work on pricing and reimbursement of medicines MANAGED ENTRY AGREEMENT (MEA) Managed entry agreement (MEA) An arrangement between a manufacturer and payer/provider that enables access to (coverage/reimbursement of) a health technology subject to specified conditions. These arrangements can use a variety of mechanisms and are usually classified into financial-based and performance-based MEA. REIMBURSEMENT RESTRICTION MODERATELY DECREASES Recent policies to reduce drug costs and the budget deficit in Croatia: impact and example to others. L. V. ončina. and . T. Strizrep (Croatian Institute for Health Insurance, Zagreb, Croatia), B. Godman (KI, Sweden), V. Vlahović-Palčevski(Rijeka UniversityHospital, Croatia)
EUROPEAN OBSERVATORY ON HEALTH SYSTEMS AND POLICIES NEW European Observatory on Health Systems and Policies NEW HIT Published by the European Observatory on Health Systems and Policies www.healthobservatory.eu/Direkt zum Inhalt
Toggle navigation
Suche
HAUPTNAVIGATION
* " class="is-active">Startseite* Fachgebiete
* Gesundheitsberufe
* Personen
* Projekte
* Schwerpunkte
* Gesundheitsökonomie und -systemanalyse* Personen
* Projekte
* Schwerpunkte
* Gesundheit und Gesellschaft* Personen
* Projekte
* Schwerpunkte
* Kompetenzzentrum Sucht* Personen
* Projekte
* Schwerpunkte
* Pharmaökonomie
* Personen
* Projekte
* Schwerpunkte
* Psychosoziale Gesundheit* Personen
* Projekte
* Schwerpunkte
* Planung und Systementwicklung* Personen
* Projekte
* Schwerpunkte
* Qualitätsmanagement und Patientensicherheit* Personen
* Projekte
* Schwerpunkte
* Evidenz und Qualitätsstandards* Personen
* Projekte
* Schwerpunkte
* Qualitätsmessung und Patientenbefragung* Personen
* Projekte
* Schwerpunkte
* Übergreifende Themen* Evaluationen
* Primärversorgung
* Zielsteuerung-Gesundheit* Publikationen
* Suche
* Jahresbericht
* GÖG Broschüre
* Newsletter
* Services
* Öffentliches Gesundheitsportal Österreichs * Vergiftungsinformation * Widerspruchsregister * Österreichischer Spitalskompass * Österreichischer Rehabilitationskompass * Österreichischer Suchthilfekompass * Nationale Koordinationsstelle für seltene Erkrankungen * Nationale Kontaktstelle für grenzüberschreitende Gesundheitsversorgung * ÖBIG – Transplant * Österreichisches Stammzellregister* Daten & Register
* Gesundheitsberuferegister* ÖGIS
* REGIS
* Versorgungsrelevanz-Gutachten * Gesundheitsberichtearchiv * PPI – Pharma-Preisinformation * Österreichisches Register für Medizinprodukte * Serviceleistungen der VIZ für Unternehmen* HTA-Guide
* Über uns
* Organisation
* Geschäftsbereiche* Geschäftsleitung
* Unternehmensorganigramm* Mission
* Mitarbeiterinnen und Mitarbeiter * Gesetzliche Grundlagen* Internationales
* Kontakt
* Presse
* Veranstaltungen
*
Fonds Gesundes Österreich*
Aktuelle Publikationen*
Daten & Register
*
Über uns
*
Fonds Gesundes Österreich*
Aktuelle Publikationen* 1
* 2
* 3
* 4
* Previous
* Next
GESUNDHEITSBERUFEREGISTER Seit 1. Juli 2018 gibt es eine Registrierungspflicht für Angehörige nachstehender Gesundheitsberufe. Auf der Website https://gbr.goeg.at/ finden Sie alle wichtigen Informationen, Formulare, Links, Videos und Ausfüllhilfen für die Registrierung bei der Gesundheit Österreich.Zur...
Weiterlesen
DAS ÖSTERREICHISCHE GESUNDHEITSWESEN KOMPAKT Im Auftrag des BMASGK erstellte die GÖG die Broschüre „Das österreichische Gesundheitssystem. Zahlen – Daten – Fakten“, die ab sofort zum Download zur Verfügung steht. In kompakter, anschaulicher und leicht verständlicher Weise gibt sie Interessierten einen Überblick über den...Weiterlesen
OFFENE STELLE IN DER GÖG Die Gesundheit Österreich GmbH sucht zum ehestmöglichen Eintritt eine Ärztin / einen Arzt für die Vergiftungsinformationszentrale (VIZ). Details zur Ausschreibung entnehmen Sie bitte der Stellenausschreibung .Weiterlesen
ANGEHÖRIGENARBEIT IN DER PALLIATIVVERSORGUNG Im Rahmen des 16. World Congress der European Association of Palliative Care in Berlin präsentierte Sabine Pleschberger (GÖG) die Ergebnisse eines dreijährigen Projekts zur Entwicklung der Angehörigenarbeit in der häuslichen Palliativversorgung. Dabei kam erstmals im deutschen...Weiterlesen
ORGAN- UND STAMMZELLTRANSPLANTATIONEN 2018 Das Koordinationsbüro für das Transplantationswesen an der GÖG veröffentlichte den Jahresbericht 2018. Im Vorjahr wurden in Österreich 795 Organtransplantationen durchgeführt und Organe von 202 verstorbenen Spendern entnommen. Ende 2018 warteten 826 Personen auf ein Organ, rund...Weiterlesen
TABAKKONSUM 2018
Der Bericht „Tabak und verwandte Erzeugnisse – Zahlen und Fakten 2018“ bietet einen Überblick über die wichtigsten Kennzahlen und Trends hinsichtlich des Konsums von Produkten wie Zigaretten, Shishas, E-Zigaretten und Kautabak sowie über die gesundheitlichen Folgendieses Konsums...
Weiterlesen
VERANSTALTUNGEN
> 19.09.2019
5. ÖPGK-Konferenz: Digitalisierung braucht Gesundheitskompetenz> 30.09.2019
Save the Date: GÖG-Colloquium | Social Prescribing in England – Umsetzung in Österreich?> 03.10.2019
Save the Date: GÖG-Colloquium | Highways to Health? Digitale Prävention und Gesundheitsförderung> 08.10.2019
Save the Date: GÖG-Colloquium | Prävention in der Gesundheitsversorgung - erste Erfahrungen in der Schweiz> 23.10.2019
4th PPRI Conference: Medicines access challenge – The value of pricing and reimbursement policies> 14.11.2019
24. ONGKG-Konferenz | Altersfreundliche Gesundheitseinrichtungen – Beiträge der Gesundheitsförderung Alle VeranstaltungenKONTAKT
Gesundheit Österreich GmbHStubenring 6
1010 Wien
kontakt@goeg.at
INFORMATION
* Kontakt
* Impressum
* Datenschutzerklärung* Sitemap
LINKS
* Bundesministerium für Arbeit, Soziales, Gesundheit undKonsumentenschutz
* Widerspruchsregister * Öffentliches Gesundheitsportal Österreichs * Fonds Gesundes Österreich * GesundheitsberuferegisterNEWSLETTER
Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0